Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Lebanon says Israeli strike killed 13 people near Palestinian refugee camp - 2Purdue Pharma's deal means money for some victims, end of Purdue company name. Here's what to know
- 3Remote Headphones: Improve Your Sound Insight
- 4Top 15 Supportable Design Brands Coming out on top
- 5Humanity is back at the moon! Artemis 2 astronauts arrive in lunar space
- As world leaders enter climate talks, people in poverty have the most at stake
- Map shows more than 1,900 measles cases across U.S.
- 6 Famous Cell phone Brands All over The Planet
- The Fragrant Small Tree Birds & Pollinators Love With Stunning Flowers In Summer
- Instructions to Redo Your Kona SUV for Improved Tasteful Allure and Usefulness
- Select Your Cherished Fish
- Ministry: New German petrol price regulation takes effect on April 1
- Tasting America: An Excursion Through Darling Cheap Food Brands
- Which One Energizes You the Most These Tech Developments
